Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5887757 | Seminars in Arthritis and Rheumatism | 2014 | 11 Pages |
Abstract
Response rates were comparable among anti-TNF agents. Overall, 5-year drug survival was below 50%, with infliximab demonstrating increased safety-related discontinuations. Remission rates are low in clinical practice. Strategies to increase effectiveness and long-term survival of anti-TNF agents in RA are needed.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Irini MD, Theodora E. MD, Paraskevi V. MD, Kyriaki A. MD, Ioannis MD, Loukas MD, Dimitrios MD, Fotini N. MD, Alexios MD, George K. MD, Pierre MD, Alexandros A. MD, FACR, Dimitrios T. MD, Prodromos MD,